GT201200228A - Procedimiento para la preparación de 2-(ciclohexilmetil)-n-{2-[(2s)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolin-7-sulfonamida - Google Patents

Procedimiento para la preparación de 2-(ciclohexilmetil)-n-{2-[(2s)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolin-7-sulfonamida

Info

Publication number
GT201200228A
GT201200228A GT201200228A GT201200228A GT201200228A GT 201200228 A GT201200228 A GT 201200228A GT 201200228 A GT201200228 A GT 201200228A GT 201200228 A GT201200228 A GT 201200228A GT 201200228 A GT201200228 A GT 201200228A
Authority
GT
Guatemala
Prior art keywords
methylpirrolidin
cyclohexylmetil
etil
tetrahydroisoquinolin
sulfonamide
Prior art date
Application number
GT201200228A
Other languages
English (en)
Inventor
Elenbaas Steven
Farr Robert Allan
Kane John Michael
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44012569&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201200228(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of GT201200228A publication Critical patent/GT201200228A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41Preparation of salts of carboxylic acids
    • C07C51/412Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A PROCEDIMIENTOS PARA PREPARAR 2-(CICLOHEXILMETIL)-N-{-[(2S)-1-METILPIRROLIDIN-2-IL]ETIL}-1,2,3,4-TETRAHIDROISOQUINOLIN-7-SULFONAMIDA, DIVERSOS COMPUESTOS INTERMEDIARIOS A LA MISMA Y SALES FARMACÉUTICAMENTE ACEPTABLES DE LA MISMA, QUE SON LIGANDOS A LOS RECEPTORES DE HISTAMINA H3, QUE PUEDEN INFLUIR EN LA SECRECIÓN DE NEUROTRANSMISORES EN EL CEREBRO Y LA PERIFERIA Y SER ÚTIL EN EL TRATAMIENTO DE ENFERMEDAD DE ALZHEIMER Y OTRAS DEMENCIAS, OBESIDAD, TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL Y OTROS.
GT201200228A 2010-03-05 2012-07-20 Procedimiento para la preparación de 2-(ciclohexilmetil)-n-{2-[(2s)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolin-7-sulfonamida GT201200228A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31106910P 2010-03-05 2010-03-05
FR1059750 2010-11-25

Publications (1)

Publication Number Publication Date
GT201200228A true GT201200228A (es) 2013-11-21

Family

ID=44012569

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201200228A GT201200228A (es) 2010-03-05 2012-07-20 Procedimiento para la preparación de 2-(ciclohexilmetil)-n-{2-[(2s)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolin-7-sulfonamida

Country Status (27)

Country Link
US (2) US8748615B2 (es)
EP (2) EP2556064B1 (es)
JP (2) JP5927126B2 (es)
KR (2) KR101783679B1 (es)
CN (2) CN103068815A (es)
AR (2) AR080375A1 (es)
AU (2) AU2011223560A1 (es)
BR (2) BR112012022234A2 (es)
CA (2) CA2789669A1 (es)
CL (2) CL2012002451A1 (es)
CO (2) CO6630099A2 (es)
CR (1) CR20120467A (es)
DO (1) DOP2012000228A (es)
EC (1) ECSP12012207A (es)
GT (1) GT201200228A (es)
IL (2) IL221339A0 (es)
MA (2) MA34142B1 (es)
MX (2) MX2012008422A (es)
NZ (2) NZ601498A (es)
PE (1) PE20130007A1 (es)
RU (2) RU2012142310A (es)
SG (2) SG183256A1 (es)
TN (1) TN2012000361A1 (es)
TW (2) TW201144284A (es)
UY (2) UY33263A (es)
WO (2) WO2011109675A2 (es)
ZA (1) ZA201205311B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR080375A1 (es) 2010-03-05 2012-04-04 Sanofi Aventis Procedimiento para la preparacion de 2-(cicloheximetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolina- 7-sulfonamida
CN102816101A (zh) * 2012-08-21 2012-12-12 江苏恒祥化工有限责任公司 一种(s)-n-甲基-2氯乙基吡咯烷的合成方法
SG11201601306QA (en) * 2013-09-09 2016-03-30 Sanofi Sa An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease
KR20200061363A (ko) * 2017-10-04 2020-06-02 셀진 코포레이션 시스-4-[2-{[(3s,4r)-3-플루오로옥산-4-일]아미노}-8-(2,4,6-트리클로로아닐리노)-9h-퓨린-9-일]-1-메틸사이클로헥산-1-카르복스아미드의 제조 공정

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4228170A (en) 1979-08-30 1980-10-14 Smithkline Corporation 7- and/or 8-Sulfur substituted 1,2,3,4-tetrahydroisoquinoline compounds
US4315935A (en) * 1980-04-14 1982-02-16 Smithkline Corporation N,N'-Bis[substituted-1,2,3,4-tetrahydroisoquinolinolyl]disulfonylimides and antiallergic compositions and method of use
GB8717374D0 (en) 1987-07-22 1987-08-26 Smith Kline French Lab Pharmaceutically active compounds
US4857301A (en) 1987-09-25 1989-08-15 Schering Corporation Sulfonamide compounds, compositions and method of use
AU7102394A (en) 1993-06-09 1995-01-03 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
GB9322976D0 (en) 1993-11-08 1994-01-05 Pfizer Ltd Therapeutic agents
GB9709303D0 (en) * 1997-05-09 1997-06-25 Smithkline Beecham Plc Compounds
US6562828B1 (en) 1998-04-10 2003-05-13 Japan Tobacco Inc. Amidine compounds
GB9816984D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
AU6123699A (en) 1998-10-16 2000-05-08 Takeda Chemical Industries Ltd. Nitrogenous fused heterocycle compounds, process for the preparation thereof andagents containing the same
KR20020005653A (ko) 1999-04-01 2002-01-17 실버스타인 아써 에이. 소르비톨 디하이드로게나제 저해제로서의 아미노피리미딘
GB9912410D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
AR025884A1 (es) 1999-10-01 2002-12-18 Takeda Pharmaceutical Compuestos de amina ciclica, su produccion y su uso
RU2256661C2 (ru) 1999-12-03 2005-07-20 Киото Фармасьютикал Индастриз, Лтд. Производные тетрагидроизохинолина и их соли и фармацевтическая композиция на их основе
FR2804429B1 (fr) 2000-01-31 2003-05-09 Adir Nouveaux derives de 4-sulfonamides piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2807434B1 (fr) 2000-04-05 2002-10-18 Hoechst Marion Roussel Inc Nouveaux derives de la 1,2,3,4-tetrahydroisoquinoleine, leur procede de preparation et leur application comme fongicides
PL361887A1 (en) 2000-10-20 2004-10-04 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
CA2425286A1 (en) * 2000-10-30 2002-05-10 Warner-Lambert Company Llc Aminoalkylpyrrolidine serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their synthesis
CA2441080A1 (en) 2001-03-23 2002-10-03 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
EP1408030B1 (en) * 2001-06-18 2006-01-04 Maruha Corporation Novel aliphatic compound, method of synthesis, and method of utilization
JPWO2003011812A1 (ja) 2001-08-01 2004-11-18 持田製薬株式会社 ヒト−β−トリプターゼ阻害活性を有する新規アミン誘導体およびそれを含有する医薬
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
EP1461311A2 (en) 2001-12-26 2004-09-29 Bayer HealthCare AG Urea derivatives as vr1-antagonists
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
EP1622916A4 (en) 2003-04-17 2008-11-05 Merck & Co Inc Heterocyclic CYCLOPENTYLTETRAHYDROISOCHINOLINE AND TETRAHYDROPYRIDOPYRIDINE MODULATORS OF CHEMOKIN RECEPTOR ACTIVITY
FR2857695B1 (fr) 2003-07-15 2007-04-20 Saint Gobain Ct Recherches Bloc pour la filtration de particules contenues dans les gaz d'echappement d'un moteur a combustion interne
AU2004313486A1 (en) 2004-01-02 2005-07-28 Merck & Co., Inc. Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity
WO2005070133A2 (en) 2004-01-20 2005-08-04 Merck & Co., Inc. 2,6-disubstituted piperidines as modulators of chemokine receptor activity
US7557124B2 (en) 2004-04-26 2009-07-07 Merck & Co., Inc. Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
EP1742919A4 (en) 2004-04-26 2010-04-28 Merck Sharp & Dohme CYCLOPENTYL TETRAHYDROISOQUINOLINE 1-SUBSTITUTED AND 1,1-DISUBSTITUTED TETRAHYDROPYRANYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
MXPA06013112A (es) 2004-05-11 2007-02-14 Incyte Corp 3-(4-heteroarilciclohexilamino)ciclopentanocarboxamidas como moduladores de receptores de quimiocinas.
FR2870846B1 (fr) 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
WO2005123089A2 (en) 2004-06-10 2005-12-29 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
EP1630158A1 (en) 2004-08-18 2006-03-01 Laboratorios Del Dr. Esteve, S.A. 5-HT7 receptor antagonists
ES2257168B1 (es) 2004-08-18 2007-06-01 Laboratorios Del Dr Esteve, S.A. Ligandos del receptor 5-ht7.
MX2007002240A (es) 2004-08-28 2007-04-20 Astrazeneca Ab Derivados de pirimidinosulfonamida como moduladores del receptor quimiocina.
SE0403086D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
DE602005014382D1 (de) 2004-12-21 2009-06-18 Smithkline Beecham Corp 2-pyrimidinyl-pyrazolopyridin-erbb-kinaseinhibitoren
EP1831157A2 (en) 2004-12-22 2007-09-12 Pfizer Limited Nonnucleoside inhibitors of hiv-1 reverse transcriptase
EP1844045B1 (en) 2005-01-26 2009-11-04 F.Hoffmann-La Roche Ag Phenyl methanone derivatives and their use as glycine transporter 1 inhibitors
DE102005015040A1 (de) 2005-03-31 2006-10-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
AR053845A1 (es) 2005-04-15 2007-05-23 Tibotec Pharm Ltd 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450
WO2006122014A2 (en) 2005-05-10 2006-11-16 Vertex Pharmaceuticals Incorporated Bicyclic derivatives as modulators of ion channels
EP1911747A1 (en) 2006-10-11 2008-04-16 Laboratorios del Dr. Esteve S.A. Sulfonamide substituted pyrazoline compounds, their preparation and use as CB1 modulators
JP5443975B2 (ja) 2007-04-27 2014-03-19 富山化学工業株式会社 新規なスルホンアミド誘導体またはその塩
EP2274280A2 (en) 2008-04-16 2011-01-19 Biolipox AB Bis-aryl compounds for use as medicaments
WO2010127272A2 (en) 2009-04-30 2010-11-04 Concert Pharmaceuticals, Inc. Hydroxyethylamino sulfonamide derivatives
MX2011012824A (es) 2009-06-26 2012-01-27 Sanofi Sa Nuevas sales de fumarato de un antagonista del receptor de histamina h3.
AR080375A1 (es) 2010-03-05 2012-04-04 Sanofi Aventis Procedimiento para la preparacion de 2-(cicloheximetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolina- 7-sulfonamida

Also Published As

Publication number Publication date
SG182576A1 (en) 2012-08-30
AR080375A1 (es) 2012-04-04
NZ601498A (en) 2014-12-24
SG183256A1 (en) 2012-09-27
JP2013521309A (ja) 2013-06-10
EP2556064B1 (en) 2014-10-15
KR101783679B1 (ko) 2017-10-10
WO2011109680A3 (en) 2012-12-20
CN103221394A (zh) 2013-07-24
KR20130038186A (ko) 2013-04-17
ZA201205311B (en) 2013-03-27
CN103068815A (zh) 2013-04-24
PE20130007A1 (es) 2013-02-01
IL221339A0 (en) 2012-10-31
WO2011109675A2 (en) 2011-09-09
TW201144284A (en) 2011-12-16
RU2012142338A (ru) 2014-04-10
CO6630099A2 (es) 2013-03-01
AU2011223560A1 (en) 2012-09-13
UY33262A (es) 2011-09-30
IL221341A0 (en) 2012-10-31
IL221341A (en) 2014-05-28
CA2787427C (en) 2017-10-10
TN2012000361A1 (en) 2014-01-30
JP5927126B2 (ja) 2016-05-25
TW201144285A (en) 2011-12-16
JP2013521308A (ja) 2013-06-10
CR20120467A (es) 2012-10-05
MX2012008422A (es) 2012-08-15
AR080374A1 (es) 2012-04-04
US8748615B2 (en) 2014-06-10
WO2011109675A3 (en) 2012-11-22
BR112012022234A2 (pt) 2015-12-15
KR20130047685A (ko) 2013-05-08
CL2012002452A1 (es) 2012-11-30
EP2542530A2 (en) 2013-01-09
CA2787427A1 (en) 2011-09-09
US8779145B2 (en) 2014-07-15
NZ602009A (en) 2015-01-30
AU2011222588A1 (en) 2012-08-23
DOP2012000228A (es) 2013-01-15
WO2011109680A2 (en) 2011-09-09
UY33263A (es) 2011-09-30
CO6630129A2 (es) 2013-03-01
EP2556064A2 (en) 2013-02-13
BR112012022356A2 (pt) 2016-08-30
RU2012142310A (ru) 2014-04-10
ECSP12012207A (es) 2013-03-28
MA34144B1 (fr) 2013-04-03
CL2012002451A1 (es) 2012-11-30
US20130123302A1 (en) 2013-05-16
US20130137718A1 (en) 2013-05-30
MX2012009413A (es) 2012-09-07
MA34142B1 (fr) 2013-04-03
AU2011222588B2 (en) 2016-09-08
CA2789669A1 (en) 2011-09-09

Similar Documents

Publication Publication Date Title
CO6970607A2 (es) Moduladores del receptor mas acoplado a la proteína g y el tratamiento de trastornos relacionados con el mismo
CU20120013A7 (es) Derivados de oxacina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
CL2014002062A1 (es) Compuesto de moleculas pequeñas que inhiben cdk8 y cdk19, excluyendo cortistatina a y otros; formulacion farmceutica; un método para tratar a un mamifero que tiene una enfermedad relacionada con cdk1 como e. de alzheimer, otras demencias, amiloidosis, y un metodo para quimioproteger un paciente que padece cancer de ovario o mama, entre otros.
DOP2013000263A (es) Compuestos de 2- (2,4,5-anilino sustituido) pirimidina derivados como moduladores de egfr utilizados para el tratamiento del cáncer
EA201592146A1 (ru) Гетероароматические соединения и их применение в качестве лигандов к дофаминовым d1-рецепторам
CY1118021T1 (el) Παραγωγο αζολιου
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
MX2016008624A (es) Inhibidores de serina/treonina cinasa.
CR11187A (es) Compuestos de quinolina adecuados para el tratamiento de trastornos que responden a la modulacion del receptor de serotonina 5-ht6
CO2017001875A2 (es) Terapia de combinación contra el alzheimer usando anticuerpos anti-n3pglu más un inhibidor bace
EA201490569A1 (ru) Полиморфная форма гидрохлорида придопидина
DOP2012000174A (es) Metodo de tratamiento
GT201200228A (es) Procedimiento para la preparación de 2-(ciclohexilmetil)-n-{2-[(2s)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolin-7-sulfonamida
UY33557A (es) Inhibidores de oxadiazol de la produccion de leucotrieno
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
GT201400242A (es) "nuevos compuestos de pirazol"
EA201691567A1 (ru) Способы лечения легких травм головного мозга
EA201691160A1 (ru) Антагонисты s1p3
AR096165A1 (es) Síntesis de 3-(5-amino-2-metil-4-oxoquinazolin-3(4h)-il)piperidin-2,6-diona
BR112017000584A2 (pt) inibidores da aldosterona sintase
CL2015001881A1 (es) Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.
PE20121403A1 (es) Nuevas sales de fumarato de un antagonista del receptor de histamina h3
BR112014024736A2 (pt) antagonista receptor de h3 para uso no tratamento de doença de alzheimer
BR112016016098A2 (pt) Compostos orgânicos